Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.45Last Year’s EPS
0.35Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 31.01%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and operational efficiency improvements, particularly in the U.S. market and logistics services. However, challenges remain in international revenue growth, service gross margin, and managing increased operating expenses. Despite these lowlights, the overall outlook is positive with raised revenue guidance and significant strategic advancements.Company Guidance
During TransMedics' first-quarter 2025 earnings call, the company provided updated financial guidance reflecting a robust performance. Total revenue for Q1 2025 reached $143.5 million, marking approximately 48% year-over-year growth and 18% sequential growth, driven by increased adoption of the OCS NOP platform for liver and heart transplants. The company's transplant services revenue rose to $55.3 million, up 56% from the previous year. Operating profit for Q1 was reported at $27.4 million, constituting 19% of total revenue, compared to 7% in Q4 2024. The gross margin improved to 61.5%. For fiscal year 2025, TransMedics raised its full-year revenue guidance to $565-$585 million, representing 28%-32% growth over 2024. The company plans to launch new heart and lung clinical programs in the second half of 2025, with expected contributions primarily in 2026. Despite external distractions, TransMedics maintained strong operational execution, underscoring resilience and support from the transplant clinical community.Record Revenue Growth
Total revenue for Q1 2025 was $143.5 million, representing approximately 48% growth year-over-year and 18% sequential growth from Q4 2024.
Strong Performance in Transplant Services
TransMedics transplant services revenue for Q1 was approximately $55.3 million, up 56% year-over-year and 18.5% sequentially.
Improved Gross Margin
Overall gross margins for Q1 improved to 61.5%, up from 59% in Q4 2024.
Significant Operating Profit Increase
Operating profit was $27.4 million in Q1, representing approximately 19% of total revenue and up significantly from 7% of total revenue in Q4 2024.
Successful Expansion in Logistics
Transplant Logistics services revenue for Q1 was $26.1 million, representing approximately 80% year-over-year and 20% sequential growth.
Raised Full-Year Revenue Guidance
Full-year 2025 revenue guidance was raised to between $565 million and $585 million, representing approximately 28% to 32% growth over full-year 2024.
---
TMDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TMDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $93.20 | $111.50 | +19.64% |
Feb 27, 2025 | $72.12 | $76.32 | +5.82% |
Oct 28, 2024 | $126.24 | $88.50 | -29.90% |
Jul 31, 2024 | $142.26 | $151.51 | +6.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does TransMedics Group Inc (TMDX) report earnings?
TransMedics Group Inc (TMDX) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is TransMedics Group Inc (TMDX) earnings time?
TransMedics Group Inc (TMDX) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TMDX EPS forecast?
TMDX EPS forecast for the fiscal quarter 2025 (Q2) is 0.45.
---